• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较两种自动化免疫分析方法(Elecsys和Lumipulse)检测的脑脊液淀粉样蛋白-β生物标志物比率与淀粉样蛋白PET状态。

Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.

作者信息

Willemse Eline A J, Tijms Betty M, van Berckel Bart N M, Le Bastard Nathalie, van der Flier Wiesje M, Scheltens Philip, Teunissen Charlotte E

机构信息

Department of Clinical Chemistry Neurochemistry Laboratory Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam the Netherlands.

Department of Neurology Alzheimer Center Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam the Netherlands.

出版信息

Alzheimers Dement (Amst). 2021 May 1;13(1):e12182. doi: 10.1002/dad2.12182. eCollection 2021.

DOI:10.1002/dad2.12182
PMID:33969174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8088096/
Abstract

INTRODUCTION

We evaluated for two novel automated biomarker assays how cerebrospinal fluid (CSF) amyloid beta (Aβ)-ratios improved the concordance with amyloid positron emission tomography (PET) positivity compared to Aβ alone.

METHODS

We selected 288 individuals from the Amsterdam Dementia Cohort across the Alzheimer's disease clinical spectrum when they had both CSF and amyloid PET visual read available, regardless of diagnosis. CSF Aβ, phosphorylated tau (p-tau), and total tau (t-tau) were measured with Elecsys and Lumipulse assays, and Aβ with Lumipulse. CSF cut-points were defined using receiver operating characteristic (ROC) for amyloid PET positivity.

RESULTS

For both Elecsys and Lumipulse the p-tau/Aβ, Aβ/Aβ, and t-tau/Aβ ratios showed similarly good concordance with amyloid PET (Elecsys: 93,90,90%; Lumipulse: 94,92,90%) and were higher than Aβ alone (Elecsys 85%; Lumipulse 84%).

DISCUSSION

Biomarker ratios p-tau/Aβ, Aβ/Aβ, t-tau/Aβ on two automated platforms show similar optimal concordance with amyloid PET in a memory clinic cohort.

摘要

引言

我们评估了两种新型自动化生物标志物检测方法,与单独检测淀粉样蛋白β(Aβ)相比,脑脊液(CSF)淀粉样蛋白β比值如何提高与淀粉样蛋白正电子发射断层扫描(PET)阳性结果的一致性。

方法

我们从阿姆斯特丹痴呆队列中选取了288名处于阿尔茨海默病临床谱系的个体,这些个体同时具备脑脊液和淀粉样蛋白PET视觉读数,无论其诊断结果如何。使用罗氏电化学发光免疫分析法(Elecsys)和日本东曹公司的Lumipulse检测法测量脑脊液中的Aβ、磷酸化tau蛋白(p-tau)和总tau蛋白(t-tau),并使用Lumipulse检测法测量Aβ。通过接受者操作特征(ROC)曲线确定淀粉样蛋白PET阳性的脑脊液切点。

结果

对于Elecsys和Lumipulse检测法,p-tau/Aβ、Aβ/Aβ和t-tau/Aβ比值与淀粉样蛋白PET的一致性同样良好(Elecsys:93%、90%、90%;Lumipulse:94%、92%、90%),且高于单独检测Aβ(Elecsys为85%;Lumipulse为84%)。

讨论

在记忆门诊队列中,两个自动化平台上的生物标志物比值p-tau/Aβ、Aβ/Aβ、t-tau/Aβ与淀粉样蛋白PET显示出相似的最佳一致性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1bc/8088096/62e937982370/DAD2-13-e12182-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1bc/8088096/01343956fc27/DAD2-13-e12182-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1bc/8088096/62e937982370/DAD2-13-e12182-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1bc/8088096/01343956fc27/DAD2-13-e12182-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1bc/8088096/62e937982370/DAD2-13-e12182-g001.jpg

相似文献

1
Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.比较两种自动化免疫分析方法(Elecsys和Lumipulse)检测的脑脊液淀粉样蛋白-β生物标志物比率与淀粉样蛋白PET状态。
Alzheimers Dement (Amst). 2021 May 1;13(1):e12182. doi: 10.1002/dad2.12182. eCollection 2021.
2
Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.基于 Lumipulse 全自动免疫分析的阿尔茨海默病脑脊液生物标志物:与韩国人群中淀粉样蛋白-β PET 和手工免疫分析的一致性:韩国人群中通过 Lumipulse 测量的 CSF AD 生物标志物。
Alzheimers Res Ther. 2021 Jan 12;13(1):22. doi: 10.1186/s13195-020-00767-3.
3
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.临床前队列中阿尔茨海默病病理学脑脊液指标与淀粉样蛋白PET状态的一致性:Lumipulse与既定免疫测定法的比较
Alzheimers Dement (Amst). 2020 Sep 13;12(1):e12097. doi: 10.1002/dad2.12097. eCollection 2020.
4
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.临床前队列中阿尔茨海默病病理学脑脊液指标与淀粉样蛋白PET状态的一致性:Lumipulse与既定免疫测定法的比较
Alzheimers Dement (Amst). 2021 Feb 6;13(1):e12131. doi: 10.1002/dad2.12131. eCollection 2021.
5
P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.脑脊液中P- tau/Aβ42和Aβ42/40的比值对淀粉样蛋白PET状态具有同等的预测价值。
Alzheimers Dement (Amst). 2021 May 18;13(1):e12190. doi: 10.1002/dad2.12190. eCollection 2021.
6
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.不同淀粉样蛋白免疫测定法与视觉淀粉样蛋白正电子发射断层扫描评估之间的一致性
JAMA Neurol. 2017 Dec 1;74(12):1492-1501. doi: 10.1001/jamaneurol.2017.2814.
7
Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.评估Elecsys和Lumipulse全自动平台与Innotest之间的一致性和诊断准确性。
Front Aging Neurosci. 2021 Mar 4;13:604119. doi: 10.3389/fnagi.2021.604119. eCollection 2021.
8
Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ and T-Tau assays for Alzheimer's disease diagnosis.用于阿尔茨海默病诊断的自动 Lumipulse 脑脊液 Aβ 和 T-Tau 分析及临床性能。
J Neurol. 2019 Sep;266(9):2304-2311. doi: 10.1007/s00415-019-09418-6. Epub 2019 Jun 10.
9
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.脑脊液生物标志物 Aβ42/40 比值比单独的 Aβ42 更能识别淀粉样 PET 阳性,在异质记忆诊所队列中。
Alzheimers Res Ther. 2022 Apr 26;14(1):60. doi: 10.1186/s13195-022-01003-w.
10
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.脑脊液 t-tau/Aβ42 比值与淀粉样蛋白 PET 状态的一致性。
Alzheimers Dement. 2020 Jan;16(1):144-152. doi: 10.1002/alz.12000.

引用本文的文献

1
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology.用于检测淀粉样蛋白病理学的临床应用中血浆磷酸化 Tau 217 的高精度全自动数字免疫测定法的分析和临床验证。
Front Neurol. 2025 Jul 9;16:1568971. doi: 10.3389/fneur.2025.1568971. eCollection 2025.
2
Sink-index: a network-based EEG marker for frontotemporal dementia and Alzheimer's disease.汇指数:一种用于额颞叶痴呆和阿尔茨海默病的基于网络的脑电图标志物。
Brain Commun. 2025 Jun 30;7(4):fcaf259. doi: 10.1093/braincomms/fcaf259. eCollection 2025.
3
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.

本文引用的文献

1
Association of amyloid-β CSF/PET discordance and tau load 5 years later.淀粉样蛋白-β 脑脊液/正电子发射断层扫描(PET)不相符与 5 年后 tau 负荷的关系。
Neurology. 2020 Nov 10;95(19):e2648-e2657. doi: 10.1212/WNL.0000000000010739. Epub 2020 Sep 10.
2
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults.认知功能未受损的老年人脑脊液β淀粉样蛋白、淀粉样蛋白PET与认知的关联
Neurology. 2020 Oct 13;95(15):e2075-e2085. doi: 10.1212/WNL.0000000000010596. Epub 2020 Aug 5.
3
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays.
阿尔茨海默病临床谱系中脑脊液淀粉样蛋白和 Tau 生物标志物的变化
JAMA Netw Open. 2025 Jul 1;8(7):e2519919. doi: 10.1001/jamanetworkopen.2025.19919.
4
Faster decline of very prodromal dementia with Lewy bodies when amyloid positive.淀粉样蛋白呈阳性时,路易体极前驱期痴呆的病情进展更快。
Alzheimers Dement (Amst). 2025 Jun 24;17(2):e70141. doi: 10.1002/dad2.70141. eCollection 2025 Apr-Jun.
5
Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristics.主观认知下降中淀粉样蛋白与抑郁和焦虑症状之间的纵向关联:人格特征的影响。
Front Psychiatry. 2025 Jun 10;16:1572174. doi: 10.3389/fpsyt.2025.1572174. eCollection 2025.
6
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis.血浆pTau181/Aβ42、pTau217/Aβ42比值及个体测量值在检测脑淀粉样变性中的比较性能
EBioMedicine. 2025 Jun 12;117:105805. doi: 10.1016/j.ebiom.2025.105805.
7
"Real-world" eligibility for anti-amyloid treatment in a tertiary memory clinic setting.三级记忆诊所环境中抗淀粉样蛋白治疗的“真实世界”适用性。
Alzheimers Dement. 2025 Jun;21(6):e70375. doi: 10.1002/alz.70375.
8
Comparison of ERlangen Score with pTau/Aβ1-42 Ratio for Predicting Cognitive Decline and Conversion to Alzheimer's Disease.用于预测认知衰退和转化为阿尔茨海默病的埃尔朗根评分与pTau/Aβ1-42比值的比较
Brain Sci. 2025 Mar 23;15(4):334. doi: 10.3390/brainsci15040334.
9
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's disease.新型脑脊液β-突触核蛋白特异性检测可提示阿尔茨海默病早期突触退变。
Alzheimers Res Ther. 2025 Apr 14;17(1):81. doi: 10.1186/s13195-025-01716-8.
10
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.阿尔茨海默病淀粉样蛋白PET和脑脊液生物标志物临床应用的考量
Alzheimers Dement. 2025 Mar;21(3):e14528. doi: 10.1002/alz.14528.
首个用于校准商业免疫分析的经过认证的β淀粉样蛋白 1-42 参考物质。
Alzheimers Dement. 2020 Nov;16(11):1493-1503. doi: 10.1002/alz.12145. Epub 2020 Aug 4.
4
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.Elecsys CSF 生物标志物免疫分析与淀粉样蛋白-PET 成像具有一致性。
Alzheimers Res Ther. 2020 Mar 31;12(1):36. doi: 10.1186/s13195-020-00595-5.
5
Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.脑脊液 t-tau/Aβ42 比值与淀粉样蛋白 PET 状态的一致性。
Alzheimers Dement. 2020 Jan;16(1):144-152. doi: 10.1002/alz.12000.
6
Amyloid-β-independent regulators of tau pathology in Alzheimer disease.阿尔茨海默病中 tau 病理的淀粉样 β 独立调节剂。
Nat Rev Neurosci. 2020 Jan;21(1):21-35. doi: 10.1038/s41583-019-0240-3. Epub 2019 Nov 28.
7
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.用于阿尔茨海默病常规诊断的 Lumipulse G 脑脊液检测的临床验证。
Alzheimers Res Ther. 2019 Nov 23;11(1):91. doi: 10.1186/s13195-019-0550-8.
8
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.在 Lumipulse 上淀粉样蛋白 PET 和 CSF 生物标志物对阿尔茨海默病的一致性。
Ann Clin Transl Neurol. 2019 Sep;6(9):1815-1824. doi: 10.1002/acn3.50873. Epub 2019 Aug 28.
9
Towards a unified protocol for handling of CSF before β-amyloid measurements.建立用于β-淀粉样蛋白检测前脑脊液处理的统一方案。
Alzheimers Res Ther. 2019 Jul 19;11(1):63. doi: 10.1186/s13195-019-0517-9.
10
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis.用于阿尔茨海默病诊断的全自动化学发光酶免疫分析的诊断性能。
Clin Chim Acta. 2019 Jul;494:74-78. doi: 10.1016/j.cca.2019.03.1612. Epub 2019 Mar 13.